کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
8612629 | 1567322 | 2018 | 28 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Borderline ER-Positive Primary Breast Cancer Gains No Significant Survival Benefit From Endocrine Therapy: A Systematic Review and Meta-Analysis
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
موضوعات مرتبط
علوم پزشکی و سلامت
پزشکی و دندانپزشکی
بیهوشی و پزشکی درد
پیش نمایش صفحه اول مقاله
چکیده انگلیسی
Endocrine responsiveness of primary breast cancers with borderline estrogen receptor expression (ER+ [1%-9%]) remains unclear. We aimed at investigating differences in endocrine responsiveness, prognosis, and clinicopathological characteristics between the ER+ (1%-9%) cohort and the ERâ cohort or ER+ (â¥10%) cohort. Eligible literature published from inception to November 20, 2016 was retrieved from the PubMed database on the basis of Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Data on survival outcomes were extracted and pooled odds ratios (ORs), 95% confidence intervals (CIs), and 2-tailed P values are reported. P values of the Ï2 test for comparison of clinicopathological characteristics among included patients in the ER+ (1%-9%) cohort and the other 2 cohorts were calculated respectively. The analysis included 6 studies with 16,606 patients. Significant differences were detected between the ER+ (1%-9%) cohort and the other 2 cohorts on the basis of clinicopathological characteristics respectively. When taking all of the patients into analysis without consideration of treatment modality, the ER+ (1%-9%) cohort presented better prognosis than the ERâ group in terms of 5-year disease-free survival (OR, 1.47; P = .046) and 5-year overall survival (OR, 1.23; P = .046). However, patients with ER+ (1%-9%) breast cancer who received endocrine therapy seemed to have a prognosis similar to those without any endocrine therapy (P = .684) and those with ERâ carcinoma who received endocrine therapy (P = .145). Patients with ER+ (â¥10%) tumors had better endocrine responsiveness compared with their ER+ (1%-9%) counterparts (OR, 0.52; P = .034, ER+ [1%-9%] vs. ER+ [â¥10%]). Our results indicate that primary breast cancer patients with ER+ (1%-9%) expression gained no significant survival benefit from endocrine therapy, but manifested overall better prognosis than those with ERâ cancer.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Clinical Breast Cancer - Volume 18, Issue 1, February 2018, Pages 1-8
Journal: Clinical Breast Cancer - Volume 18, Issue 1, February 2018, Pages 1-8
نویسندگان
Tong Chen, Ning Zhang, Meena S. Moran, Peng Su, Bruce G. Haffty, Qifeng Yang,